Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (959)	9/1/1998 3:40:00 AM
From: Bruce Olsten	Respond to of 1016

<<If you can't get an erection pay $23 and poke a stick in it. If that doesn't work, cinch it up with a rubber band and poke a stick in it and it will work less than 50% of the time. In the absence of other less costly, less invasive, less effective choices, there will be a market for this stuff. In the presence of less costly, less invasive and more effective choices (Viagra now, more to come)the market will consist of the small number of really motivated people who have failed the preferred choices.>> Dale, you hit the ...uhhh... nail right on the head!

To: BDR who wrote (959)	9/1/1998 11:28:00 AM
From: Bob Trocchi	Read Replies (1) \| Respond to of 1016

Dale. The following announcement came out this a.m. and in it VIVUS states they have engaged an investment banker to look at strategic options for the company including selling it. See article below. I have been away for awhile. Is this old news? Do you figure it is time to cover? Kinda hate to cover as VVUS is a real old friend. With this news however can it pop to over 5 again to short it again? Regards BobT. Vivus appoints interim CFO MOUNTAIN VIEW, Calif., Sept 1 (Reuters) - Vivus Inc., which makes impotence treatments for men, said Tuesday it had named Richard Walliser as interim chief financial officer. The company said in a statement that Walliser succeeded David Yntema, who resigned Aug. 31. Vivus said Walliser has served as CFO and chief operating officer of several start-up and turnaround companies. Vivus said last week it had retained an investment banker to look at strategic options, including selling the company. The company said it had been hurt by Pfizer Inc.'s (PFE - news) launch of the impotence drug Viagra biz.yahoo.com

To: BDR who wrote (959)	9/6/1998 10:09:00 PM
From: VLAD	Read Replies (2) \| Respond to of 1016

Very crude and crass remark coming from a supposed doctor. MUSE was extremely popular last year when the alternatives were to stick an needle in it or have a plastic bubble sutured into it. Not a bad alternative considering the options. Looks to me like the magic blue pill is rapidly loosing its magic. No MUSE certainly is not perfect but if marketed properly (50 sales people calling on 8,000 urologists in 1997 IMO is not effective marketing) it can make a small biotech company such as Vivus very profitable. It should be interesting to see how domestic sales do if Astra partners domestically. We can then see if it is the product or lack of marketing. Time will tell.